Loading stock…

Spyre Therapeutics, Inc. (SYRE) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Spyre Therapeutics, Inc.

SYREMarket cap $7.13BPrice $80.8

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops long-acting antibody therapies for inflammatory bowel disease, aiming to let patients dose just a few times a year instead of weekly. Backed by Fairmount and Foresite, it's betting biology, not marketing, wins the next IBD drug race.

In Bastion Portfolios?

52W Return+260%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)na–

Revenue Forecast

Rev CAGR (1y)na–

Rev CAGR (3y)na–

Rev CAGR (5y)na–

Earnings Forecast

EPS Growth Y+1Loss1

EPS Growth Y+2Loss1

EPS Growth Y+3Loss1

Quality

Margins

EBIT Marginna–

Net Income Marginna–

Free Cash Flow Marginna–

Debt

Net Debt/EBITDAna–

Efficiency

ROE-24%1

ROA-21%1

Earnings Stabilityna–

GEAR+VERY WEAK1

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)na–

P/E Ratio (Forward 3y)na–

P/BV7.52

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwdna–

Yield

Free Cash Flow Yieldna–

Dividend Yieldna–

Momentum

Short term

1 month return-11%2

3 month return-15%2

YTD return+147%10

Mid term

Price vs 52wHigh73%4

1 year return+357%10

Long term

3 year return+588%10

5 year return-58%1

Risk Shield

Price Risk

Beta1.91

Volatility69%2

Free Cash Flow

Free Cash Flow Marginna–

Free Cash Flow Yieldna–

Quality

ROCE-35%1

Earnings Stabilityna–

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

SYRESpyre Therapeutics

Revenue FY23$1M

GROWTH RATING↗

VERY WEAK1 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY+1Loss1

EPS growth, FY+2Loss1

EPS growth, FY+3Loss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 99% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE34 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-15%2

YTD return+147%10

MID & LONG-TERM▾SCORE

% of 52-week high73%4

1-year return+357%10

3-year return+588%10

5-year return-58%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 357% over the past year, but 27% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+147%).

WATCH

Average long-term results. Multi-year returns are middling (+588% over three years and -58% over five), roughly average for the market.

WEAKNESSES

The stock is underperforming over the past month (-11%) and over three months (-15%).

BOTTOM LINE

Mixed Momentum

Horizons disagree or sit near the middle of the pack. Momentum investors may want a clearer trend before sizing up. The one thing to watch: the stock is underperforming over the past month and over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Spyre Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

SYRESpyre Therapeutics

Revenue FY23$1M

GROWTH RATING↗

VERY WEAK1 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGRna–

Revenue, next 1Yna–

Revenue, next 3Y, CAGRna–

Revenue, next 5Y, CAGRna–

EARNINGS FORECAST▾SCORE

EPS growth, FY+1Loss1

EPS growth, FY+2Loss1

EPS growth, FY+3Loss1

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

Revenue held flat over the last 3 years and is set to keep growing around 0%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 99% of companies worldwide.

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE34 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-15%2

YTD return+147%10

MID & LONG-TERM▾SCORE

% of 52-week high73%4

1-year return+357%10

3-year return+588%10

5-year return-58%1

MOMENTUM ASSESSMENT

STRENGTHS

It's up 357% over the past year, but 27% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming so far this year (+147%).

WATCH

Average long-term results. Multi-year returns are middling (+588% over three years and -58% over five), roughly average for the market.

WEAKNESSES

The stock is underperforming over the past month (-11%) and over three months (-15%).

BOTTOM LINE

Mixed Momentum

04Value

Are you paying a fair price for it?

Stop guessing on Spyre Therapeutics, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community